Cambridge Investment Research Advisors Inc. Has $2.63 Million Stake in Smith & Nephew SNATS, Inc. (NYSE:SNN)

Cambridge Investment Research Advisors Inc. raised its stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 19.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 72,185 shares of the medical equipment provider’s stock after acquiring an additional 11,797 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Smith & Nephew SNATS were worth $2,628,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of SNN. Bessemer Group Inc. raised its stake in Smith & Nephew SNATS by 400.2% during the 3rd quarter. Bessemer Group Inc. now owns 2,781 shares of the medical equipment provider’s stock valued at $102,000 after acquiring an additional 2,225 shares during the last quarter. Paloma Partners Management Co purchased a new position in shares of Smith & Nephew SNATS during the 1st quarter worth approximately $200,000. Greenleaf Trust purchased a new position in shares of Smith & Nephew SNATS during the 2nd quarter worth approximately $207,000. HighTower Advisors LLC purchased a new position in shares of Smith & Nephew SNATS during the 1st quarter worth approximately $242,000. Finally, Quantbot Technologies LP raised its stake in shares of Smith & Nephew SNATS by 270.0% during the 2nd quarter. Quantbot Technologies LP now owns 7,277 shares of the medical equipment provider’s stock worth $253,000 after buying an additional 5,310 shares in the last quarter. 6.63% of the stock is owned by hedge funds and other institutional investors.

Shares of Smith & Nephew SNATS, Inc. (SNN) traded down $0.17 during trading hours on Monday, reaching $35.68. The company’s stock had a trading volume of 549,598 shares, compared to its average volume of 496,061. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.08 and a current ratio of 2.18. Smith & Nephew SNATS, Inc. has a 52-week low of $28.45 and a 52-week high of $40.43.

A number of equities analysts have recently issued reports on SNN shares. Zacks Investment Research downgraded Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Tuesday, September 19th. Canaccord Genuity started coverage on Smith & Nephew SNATS in a report on Wednesday, October 11th. They issued a “buy” rating and a $42.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $42.50.

COPYRIGHT VIOLATION WARNING: “Cambridge Investment Research Advisors Inc. Has $2.63 Million Stake in Smith & Nephew SNATS, Inc. (NYSE:SNN)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/04/cambridge-investment-research-advisors-inc-has-2-63-million-holdings-in-smith-nephew-snats-inc-snn.html.

About Smith & Nephew SNATS

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Institutional Ownership by Quarter for Smith & Nephew SNATS (NYSE:SNN)

Receive News & Ratings for Smith & Nephew SNATS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply